Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Lentiviral vectors are increasingly popular as gene delivery tools for cell and gene therapies. Their value has been demonstrated within CAR-T and TCR therapies for blood malignancies that don’t ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

Lentiviral vectors are one of the foundational technologies of cell and gene therapy. Along with adenoviral vectors, they are one of the most widely used means of introducing genetic information into ...

Opportunities in viral vector manufacturing arise from rising demand for GMP-grade materials and increasing gene therapy ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

As more cell, gene and immunotherapy applications emerge for lentiviral vectors, demand for their production continues to rise. With its move last week into a larger manufacturing facility, CDMO ...

The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is becoming of higher importance. Lentiviruses are enveloped viruses that are rather ...